

## [About the Guidance](#)

New direct-acting antiviral agents (DAAs) capable of curing hepatitis C virus (HCV) infection have been approved for use in the United States. The initial DAAs were approved in 2011 and many others have since followed, including 2 new pangenotypic regimens in 2017. As new information is presented at scientific conferences and published in peer-reviewed journals, health care practitioners have expressed a need for a credible source of unbiased guidance on how best to treat their patients with HCV infection. To provide healthcare professionals with timely guidance, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) have developed a web-based process for the rapid formulation and dissemination of evidence-based, expert-developed recommendations for hepatitis C management. New sections will be added, and the recommendations will be updated on a regular basis as new information becomes available.

**The following pages include information about the Guidance and this web site:**

- [Recent Announcements](#)
- [Supporting Organizations](#)
- [HCV Guidance Panel](#)
- [Disclosure Information](#)
- [Process](#)
- [How to Cite and Request Permission to Reprint or Use Content in the Guidance](#)
- [Guidelines Survey](#)
- [Website Policies](#)
- [Contact Us](#)

### **Funding:**

The Guidance is supported and independently funded by AASLD and IDSA. CDC provided financial support to gather and review evidence related to hepatitis C screening and testing. No industry support was used for the development of this Guidance.

[Read More](#)